Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 1 hour 13 min ago

Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology

Wed, 12/17/2014 - 13:27
Dr. Yang led Janssen's prostate cancer and solid tumor therapeutic area in the U.S. PLYMOUTH MEETING, Pa., Dec. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Inovio Pharmaceuticals, Inc. (INO) announced today the appointment of Zane Yang, M.D. ...
Biopharmaceuticlas, Oncology, Personnel
Inovio Pharmaceuticals

United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change

Wed, 12/17/2014 - 13:14
Roger Jeffs, Ph.D. named President and Co-Chief Executive Officer David Zaccardelli, Pharm.D. named Executive Vice President and Chief Operating Officer SILVER SPRING, Md., Dec. 17, 2014 -- (Healthcare Sales & Marketing Network) -- United Therapeuti...
Biopharmaceuticals, Personnel
United Therapeutics

CVRx(R) Granted Humanitarian Device Exemption Approval from FDA for Barostim neo legacy(TM) Hypertension Therapy Device

Tue, 12/16/2014 - 13:12
MINNEAPOLIS, Dec. 16, 2014 -- (Healthcare Sales & Marketing Network) -- CVRx, Inc., a privately held medical device company, announced today that it has received Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration (FDA)...
Devices, Cardiology, FDA
CVRx, Barostim Therapy, Barostim neo, hypertension

Crescendo Biologics' Receives Further Investment from Astellas Venture Management to Develop Novel Humabody(TM) Therapeutics Targeting Immune Checkpoint Inhibitors

Tue, 12/16/2014 - 13:01
CAMBRIDGE, England, December 16, 2014 -- (Healthcare Sales & Marketing Network) -- Crescendo Biologics Limited (Crescendo) today announces a further equity investment from Astellas Venture Management (AVM) to support the discovery and development of new H...
Biopharmaceuticals, Oncology, Venture Capital
Crescendo Biologics, Humabody

Novartis gains FDA approval for Signifor(R) LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder

Tue, 12/16/2014 - 12:36
Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels(1) Signifor LAR, a next-generation somatostatin analog, provides a new option for patients with acromegaly with inadequately contr...
Biopharmaceuticals, FDA
Novartis, Acromegaly, Signifor LAR, pasireotide

Idera Announces Several Key Additions to Management Team

Mon, 12/15/2014 - 19:18
CAMBRIDGE, Mass., Dec. 15, 2014 -- (Healthcare Sales & Marketing Network) -- Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed ...
Biopharmaceuticals, Personnel
Idera Pharmaceuticals

Apricus Biosciences Appoints Barbara Troupin, M.D. as Chief Medical Officer

Mon, 12/15/2014 - 18:58
Company Also Announces Additional Senior Management Change SAN DIEGO, Dec. 15, 2014 -- (Healthcare Sales & Marketing Network) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, to...
Biopharmaceuticals, Personnel
Apricus Biosciences

Volcano Announces 1,000th System Activated with its iFR(R) (instant wave-Free Ratio(TM)) Modality Worldwide

Mon, 12/15/2014 - 18:48
SAN DIEGO, Dec. 15, 2014 -- (Healthcare Sales & Marketing Network) -- Volcano Corporation (VOLC), a leading company focused on improving patient and economic outcomes on a global basis by developing and delivering innovative minimally invasive coronary an...
Devices, Interventional Cardiology
Volcano, wave-Free Ratio, iFR Modality, Verrata , Pressure Guide Wire

Sanofi Pasteur Announces FDA Approval of Fluzone(R) Intradermal Quadrivalent (Influenza Vaccine) for Adults

Fri, 12/12/2014 - 15:54
The first and only four-strain influenza vaccine option administered intradermally Helps protect adults 18 through 64 years of age against an additional influenza B strain SWIFTWATER, Pa., Dec. 12, 2014 -- (Healthcare Sales & Marketing Network) -- S...
Biopharmaceuticals, FDA
Sanofi Pasteur, Fluzone, influenza

Devon Medical Products Launches New Nature’s Bond Electric Breast Pump

Thu, 12/11/2014 - 16:12
Nature’s Bond Helps Breast Feeding Moms KING OF PRUSSIA, Pa.--(Healthcare Sales & Marketing Network)--Devon Medical Products, medical device manufacturer, is proud to announce the launch of the Nature’s Bond® Electric Breast Pump. The Nature’s Bond ...
Devices, Product Launch
Devon Medical Products, Breast Pump

CVRx(R) Granted CE Marking of the Barostim neo System(TM) for Conditional MRI Compatibility

Thu, 12/11/2014 - 15:58
MINNEAPOLIS, Dec. 11, 2014 -- (Healthcare Sales & Marketing Network) -- CVRx, Inc., a privately held medical device company, announced today that CE Marking has been granted to expand labeling of the Barostim neo System™ as MR Conditional, or safe for use...
Devices, Cardiology, Regulatory
CVRx, Barostim neo System, Magnetic Resonance Imaging

Jean Boulle Group Announces Successful First Human Implants of the Nickel-Titanium Tendyne Transcatheter Mitral Valve

Wed, 12/10/2014 - 14:02
LUXEMBOURG, Dec. 10, 2014 -- (Healthcare Sales & Marketing Network) -- Boulle Medtech Ltd., a Jean Boulle Group private company focusing on medical technology, and founding investor of Tendyne Holdings, Inc. ("Tendyne"), is pleased to announce t...
Devices, Interventional Cardiology
Jean Boulle Group, Boulle Medtech, Tendyne, Transcatheter Mitral Valve

Optomeditech Gets $ 2.5 Million in Funding and CE-Mark for its OptiVein(R) System to Increase First Attempt Success Rate in IV Catheter Insertion

Wed, 12/10/2014 - 13:56
HELSINKI and ATLANTA, December 10, 2014 -- (Healthcare Sales & Marketing Network) -- Optomeditech Ltd (http://www.optomeditech.com ) today announced a $ 2.5 million funding round led by Lifeline Ventures and Sitra, The Finnish Innovation Fund. Earlier thi...
Devices, Venture Capital
Optomeditech, OptiVein

Gore Receives CE Mark Approval for GORE(R) VIABAHN(R) Endoprosthesis for Revision of Arteriovenous Access

Wed, 12/10/2014 - 13:52
Flexibility and Durability to Aid Hemodialysis Patients FLAGSTAFF, Ariz.--(Healthcare Sales & Marketing Network)--W. L. Gore & Associates, Inc. (Gore) today announced that the GORE® VIABAHN® Endoprosthesis has received CE Mark approval to improv...
Devices, Regulatory
W. L. Gore, VIABAHN Endoprosthesis, dialysis access

Leica Microsystems Announces New Representation for Southern California Medical Market

Tue, 12/09/2014 - 19:31
BUFFALO GROVE, Ill., Dec. 9, 2014 -- (Healthcare Sales & Marketing Network) -- Leica Microsystems, a technology leader in microscope and image analysis solutions, announces new market representation for its neurosurgical, ophthalmic, otolaryngologic, dent...
Devices, Distribution
Leica Microsystems

Cohera Medical, Inc.(R) Submits Investigational Device Exemption to FDA for Clinical Trial of its Sylys(R) Surgical Sealant

Tue, 12/09/2014 - 15:01
Breakthrough Surgical Sealant Designed to Help Reduce Anastomotic Leaks for Patients Undergoing Gastrointestinal Resections PITTSBURGH, Dec. 9, 2014 -- (Healthcare Sales & Marketing Network) -- Cohera Medical, Inc., a leading innovator and developer of...
Devices, Surgery, FDA
Cohera Medical, surgical adhesive, Sylys, surgical sealant

Zydus Launches World's First Biosimilar of Adalimumab

Tue, 12/09/2014 - 13:44
Access to this therapy will impact 12 million people suffering from auto immune disorders like rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosin Spondylitis in India DELHI, India, December 9, 2014 -- (Healthcare S...
Biopharmaceuticals, Product Launch
Zydus Cadila, Exemptia , Adalimumab, Biosimilar

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong